Recruiting
Phase 1 / Phase 2
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
About this study
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
- Condition
- Aggressive NK Cell Leukemia
- Tested
- PPMX-T003
- Sponsor
- Hiroshima University Hospital
Who can join
- Age
- 18 to 70 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Maximum age: 70 years
- Study condition: Aggressive NK Cell Leukemia
- Patients diagnosed with ANKL (regardless of whether the disease is first or recurrent) based on diagnostic criteria developed with reference to the World Health Organization (WHO) 4th edition (2017) criteria.
Exclusion 1
- Patients eligible to receive chemotherapy as treatment for ANKL
Where
1 site, 1 recruiting
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Contact
-
Kiyoshi Ando
+81 82-257-5555 andok@keyaki.cc.u-tokai.ac.jp
Potential match only. Final eligibility is determined by the study team.